Detalles de la búsqueda
1.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Mult Scler
; 28(3): 429-440, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34240656
2.
A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Diabetes Obes Metab
; 22(7): 1111-1121, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32077207
3.
A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody.
Diabetes Obes Metab
; 20(9): 2075-2084, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29749030
4.
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
Mult Scler
; 21(7): 885-93, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25392325
5.
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.
Hepatology
; 49(5): 1460-8, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19353740
6.
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
Hepatology
; 47(3): 817-26, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18302285
7.
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Heart Fail Rev
; 14(4): 277-87, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19238540
8.
Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.
Clin Drug Investig
; 29(12): 757-65, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19888782
9.
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env.
Clin Ther
; 41(9): 1737-1746, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31311668
10.
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.
MAbs
; 8(5): 854-60, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27030142
11.
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
Mult Scler Relat Disord
; 9: 95-100, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27645352
12.
Treatment against human endogenous retrovirus: a possible personalized medicine approach for multiple sclerosis.
Mol Diagn Ther
; 19(5): 255-65, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26376649
13.
Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
MAbs
; 7(1): 265-75, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25427053
14.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.
J Neuroimmunol
; 285: 68-70, 2015 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26198921
15.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Clin Ther
; 34(12): 2268-78, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23200102
Resultados
1 -
15
de 15
1
Próxima >
>>